All In Biotech

NDA 204150 · Alembic Pharms LTD

Desvenlafaxine

Desvenlafaxine · Oral · Serotonin and Norepinephrine Reuptake Inhibitor

Last checked: Nov 21, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Mar 4, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

89

37 Phase 3, 4 recruiting

FAERS reports

5,261

3,264 serious, 457 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.1)]. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.1)] . Desvenlafaxine is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing...

What it is approved for

From the label in effect Aug 7, 2023.

Desvenlafaxine is indicated for the treatment of adults with major depressive disorder (MDD) [see Clinical Studies (14)] . Desvenlafaxine is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with major depressive disorder (MDD) (1).

Mechanism: The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 4, 2013 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
2 products under this application
  • DESVENLAFAXINE · DESVENLAFAXINE 50MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • DESVENLAFAXINE · DESVENLAFAXINE 100MG · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Desvenlafaxine" as an intervention, any sponsor and status, largest first.

All 89 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective718
  • off label use369
  • nausea351
  • toxicity to various agents304
  • headache299
  • anxiety297
  • fatigue284
  • depression245
  • dizziness234
  • completed suicide214
  • drug interaction208
  • overdose205

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20084
200911
201043
201128
201268
201361
201436
2015118
201682
2017297
2018249
2019372
2020472
2021492
2022674
2023630
2024578
2025560
2026486

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 125 on PubMed

Sponsor: Alembic Pharms LTD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.